NASDAQ · ANL
Healthcare · Biotechnology
$13.25
Up+$0.39 (+3.03%)
Updated Aug 15, 2026, 9:44 AM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
ANL closed at $13.25 after 21 trading sessions, up 14.92% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $12.73 | $13.325 | $12.615 | $13.25 | 56.29K |
| Aug 13, 2026 | $13.18 | $13.18 | $12.50 | $12.86 | 78.58K |
| Aug 12, 2026 | $13.08 | $13.42 | $12.48 | $13.09 | 125.32K |
| Aug 11, 2026 | $13.17 | $13.38 | $12.50 | $13.08 | 134.8K |
| Aug 10, 2026 | $13.30 | $13.84 | $12.80 | $13.23 | 165.19K |
| Aug 7, 2026 | $14.00 | $14.70 | $13.00 | $13.28 | 270K |
| Aug 6, 2026 | $13.00 | $13.97 | $12.92 | $13.84 | 316.67K |
| Aug 5, 2026 | $13.00 | $13.35 | $12.86 | $13.07 | 111.5K |
| Aug 4, 2026 | $12.87 | $13.88 | $12.10 | $13.00 | 179.34K |
| Aug 3, 2026 | $12.99 | $13.41 | $12.70 | $12.99 | 216.58K |
| Jul 31, 2026 | $13.00 | $13.28 | $12.465 | $13.00 | 120.41K |
| Jul 30, 2026 | $12.21 | $13.22 | $11.67 | $13.00 | 157.67K |
| Jul 29, 2026 | $12.69 | $12.69 | $11.98 | $12.11 | 86.25K |
| Jul 28, 2026 | $11.97 | $12.88 | $11.51 | $12.69 | 201.38K |
| Jul 27, 2026 | $13.04 | $13.04 | $11.908 | $12.06 | 127.85K |
| Jul 24, 2026 | $13.15 | $13.15 | $12.04 | $12.50 | 130.7K |
| Jul 23, 2026 | $13.25 | $13.50 | $12.975 | $13.22 | 145.03K |
| Jul 22, 2026 | $12.75 | $13.30 | $12.17 | $13.26 | 180.17K |
| Jul 21, 2026 | $11.99 | $13.30 | $11.501 | $13.00 | 315.13K |
| Jul 20, 2026 | $11.51 | $12.10 | $10.34 | $11.98 | 392.49K |
| Jul 17, 2026 | $10.88 | $11.80 | $10.72 | $11.53 | 569.05K |
The latest Smart Investors Daily articles mentioning ANL.
ANL research
Company profile and research snapshot.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 22, 2026 | Cantor Fitzgerald | Overweight | — |
| May 28, 2026 | Oppenheimer | Outperform | — |
| May 14, 2026 | Jones Trading | Buy | — |
| Apr 20, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 13, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 3, 2026
First-in-class pan-RAS(ON) ADC is cleared for clinical developmentDesigned to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity.IND submissions to U.S. FDA and China NMPA are in
SeekingAlpha · Jul 31, 2026
AN9025âs intermittent-weekly arm is now dosing, but the first meaningful human readout is still expected in the first half of 2027.
Benzinga · Jul 16, 2026
"Dosing the first U.S. patient with AN9025 on an intermittent weekly schedule is a significant milestone and advances our clinical strategy to evaluate AN9025 with a differentiated approach. We believe based on our
Benzinga · Jun 22, 2026
Cantor Fitzgerald analyst Li Watsek initiates coverage on Adlai Nortye (NASDAQ:ANL) with a Overweight rating.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ANL.
